IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Case Study: Diabetes and Allied Complications.

Piyush M Bhingardive, Vaishnavi B Bhapkar, Rajshree B Berad, Chavan Anuradha

SSPM's Dr. N. J. Paulbuddhe College Of Pharmacy, Ahmednagar.

Corresponding Author:

Mr. Bhingardive P.

B. Pharm

Miss Bhapkar V

B Pharm

Miss Berad R

B Pharm

Prof. Chavan A

HOD,

SSPM's Dr. N. J. Paulbuddhe College Of Pharmacy, Ahmednagar, India.

Abstract: We ran a health survey with the help of google forms which provided concise data of the individuals including their medications. This research investigates the status of diabetes and its associated complications in the Indian population. Utilizing a dataset of studied individuals, this study analyzes demographic, health-related, and diabetes-specific metrics to draw a comprehensive picture of diabetes management and its challenges in India. The paper assesses various factors, such as age at detection, blood glucose levels, medication usage, comorbidities like hypertension and diabetic retinopathy, as well as economic considerations impacting medication accessibility. Key findings highlight the heterogeneity in diabetes onset, control, and management strategies, underscoring the complex interplay between health education, healthcare access, and socioeconomic status. The research underscores the need for individualized care plans, increased health literacy, and improved affordability of diabetes care. This research aims to contribute to the dialogue on enhancing diabetes care in India, poised on the cusp of a diabetes epidemic, and explores the broader implications for public health policy and patient empowerment.

Keywords: Name, Contact Number, Gender, Weight, Height, Age, Blood Group, Community, Occupation, Education, Address, Chronic Disease, Diabetes Detection, Blood Glucose Level, Prescription, Medicines, Dosage, Brand Name, Company Name, Disease History, Hypertension, Diabetic Retinopathy, Hb1Ac Value, Medication Affordability, rationalization.

Introduction: Diabetes is a chronic, metabolic disease characterized by elevated levels of blood glucose (or blood sugar), which leads over time to serious damage to the heart, blood vessels, eyes, kidneys and nerves. The most common is type 2 diabetes, usually in adults, which occurs when the body becomes resistant to insulin or doesn't make enough insulin. In the past 3 decades the prevalence of type 2 diabetes has risen dramatically in countries of all income levels. Type 1 diabetes, once known as juvenile diabetes or insulin-dependent diabetes, is a chronic condition in which the pancreas produces little or no insulin by itself. [3]. For people living with diabetes, access to affordable treatment, including insulin, is critical to their survival. There is a globally agreed target to halt the rise in diabetes and obesity by 2025. About 422 million people worldwide have diabetes, the majority living in low-and middle-income countries, and 1.5 million deaths are directly attributed to diabetes each year. Both the number of cases and the prevalence of diabetes have been steadily increasing over the past few decades.

Type 1 diabetes cannot currently be prevented. Effective approaches are available to prevent type 2 diabetes and to prevent the complications and premature death that can result from all types of diabetes. These include policies and practices across whole populations and within specific settings (school, home, workplace) that contribute to good health for everyone, regardless of whether they have diabetes, such as exercising regularly, eating healthily, avoiding smoking, and controlling blood pressure and lipids. [4]

The starting point for living well with diabetes is an early diagnosis – the longer a person lives with undiagnosed and untreated diabetes, the worse their health outcomes are likely to be.[5] Easy access to basic diagnostics, such as blood glucose testing, should therefore be available in primary health care settings. Patients will need periodic specialist assessment or treatment for complications. [6]

A series of cost-effective interventions can improve patient outcomes, regardless of what type of diabetes they may have. [7] These interventions include blood glucose control through a combination of diet, physical activity and, if necessary, medication; control of blood pressure and lipids to reduce cardiovascular risk and other complications; and regular screening for damage to the eyes, kidneys and feet to facilitate early treatment. [1](www.who.int/health-topics/diabetes#tab=tab_1 Last accessed on March 16, 2024) [8]

Latest Trends in Diabetes management and incidence in India: India now has more than 101 million people living with diabetes compared to 70 million people in 2019, according to an ICMR study published in the UK medical journal 'Lancet'. While the numbers are stabilising in some developed states, they are increasing at an alarming rate in many others, "warranting urgent state-specific interventions", the study notes. At least 136 million people, or 15.3% of the population, have prediabetes. [9]

The highest prevalence of diabetes was observed in Goa (26.4%), Puducherry (26.3%) and Kerala (25.5%). The national average is 11.4%. The study, however, warns of an explosion of diabetes cases in states with lower prevalence, such as UP, MP, Bihar and Arunachal Pradesh, over the next few years. "In Goa, Kerala, Tamil Nadu, and Chandigarh there are fewer pre-diabetes cases compared to diabetes cases. In Puducherry and Delhi, they are nearly equal and so we can say the disease is stabilizing," said the study's first author, Dr Ranjit Mohan Anjana, who is president of the Madras Diabetes Research Foundation. But in states with lower incidence of diabetes, scientists have recorded a greater number of people with pre-diabetes.

TABLE 1

'36% HAVE HYPERTENSION'

While 11.4% of India's the population is diabetic,
15.3% have prediabetes

Ratio of diabetic to prediabetic people is 1:1 in
Delhi, 1:1.2 in Maha, 1:1.5 in Haryana and 1:3.8 in UP

35.5% of people have hypertension and 81.2% dyslipidemia(abnormal levels of cholesterol)

While 28.6% Indians have
generalised obesity, 39.5%
have abdominal obesity

WORST AFFECTED	DM %	PRE-DM %
Goa	26.4	20.3
Puducherry	26.3	25.8
Kerala	25.5	18.3
Chandigarh	20.4	15.6
Delhi	17.8	18
Tamil nadu	14.4	10.2
West bengal	13.7	23.5

For instance, table 1 UP has a diabetic prevalence of 4.8%, the lowest in the country, but 18% arepre-diabetics compared to the national average 15.3%. “For every person with diabetes in UP, there are nearly four people with pre-diabetes. A pre-diabetic is a person with a higher-than-normal blood sugar level but not high enough to be considered type-2 diabetes. Without lifestyle changes, adults and children with pre-diabetes are at high risk of developing diabetes. Where there is no way to say how pre-diabetics will turn diabetic, doctors say they follow the rule of thirds. “A third of people with pre-diabetes will get diabetes in a few years and another one-third may remain pre-diabetic. The remaining may reverse the condition due to various factors, including a healthy diet, lifestyle, and exercise. For the study, scientists screened more than 1 lakh people from rural and urban areas between October 18, 2008 and December 17, 2020. In 2019, the survey showed that there were 74 million people with diabetes in India. Two years later, when the survey added all the low-prevalence NE states and omitted some of the high-prevalence states, the prevalence dropped to 72 million. “This time, we included 31 states and UTs. The weighted prevalence is now reflecting the ground reality. Other risk factors, such as hypertension, cholesterol levels and obesity, are also high. This increases risks of cardiac arrest, stroke, and kidney disease. According to the survey, at least 35.5% of the population has hypertension and 81.2% have abnormal levels of cholesterol (dyslipidemia).While 28.6% have generalised obesity, 39.5% were found to have abdominal obesity. There is huge variation in prevalence between the states and hence every state will have to look at different measures to prevent health complications, said ICMR. (Diabetes in India: 100 million plus in India now diabetic, up 44% in 4 years says ICMR study | India News - Times of India (indiatimes.com) Last accessed on 16th March 2024) [2], [10]

Data Analysis of Indian Diabetic Patients:

In our recent health survey conducted across various localities in Ahmednagar, we aimed to comprehensively assess the prevalence and associated parameters of Diabetes Mellitus within the community. Leveraging Google Forms, we conducted interviews and gathered data from a diverse sample of individuals, including households,

pathology laboratories, diabetologists, and hospitals. Our diligent efforts resulted in the collection of information from over 450 individuals, providing us with a robust dataset for analysis. [11]

Of the individuals surveyed, a notable finding was that 105 individuals had been diagnosed with Diabetes Mellitus. This highlights the significance of our study in understanding the prevalence and impact of this chronic condition within the community. [12]

Our data encompasses a wide range of parameters relevant to diabetes management and its associated complications. These include demographic information such as name, age, anthropometric measurements such as height and weight, as well as crucial clinical indicators such as pre and post-prandial blood glucose levels, HbA1c values, ongoing medications, prescriptions and the presence of other comorbidities like hypertension and retinopathy. [13]

Through rigorous data analysis, we aim to uncover valuable insights into the epidemiology, management, and associated complications of Diabetes Mellitus in Ahmednagar. This analysis holds the potential to inform public health strategies, healthcare interventions, and personalized care approaches for individuals affected by this prevalent condition within our community.

We've discussed the dataset below, thoroughly. [14]

1. Demographic information.

• Gender



In our case study examining the prevalence of diabetes mellitus (DM) among patients in Ahmednagar, we uncovered an intriguing disparity in gender distribution. Drawing from a comprehensive dataset collected through household surveys, pathology laboratories, diabetologists' clinics, and hospitals, we found that 48.6% of identified diabetic patients were female, while 51.4% were male.

This gender imbalance prompts a deeper inquiry into the underlying factors shaping diabetes prevalence across genders within the Ahmednagar community. We seek to understand whether biological, socio-cultural, behavioral, or environmental determinants contribute to the observed disparity. Additionally, we aim to explore how gender intersects with diabetes risk factors, clinical manifestations, treatment responses, and health outcomes. [15]

Recognizing the significance of gender-sensitive approaches in healthcare research and delivery, our study aims to shed light on these nuances. By contextualizing our findings within the broader landscape of diabetes epidemiology, we hope to inform targeted strategies for diabetes prevention, management, and care delivery in Ahmednagar and beyond. [16]

Through rigorous analysis and interpretation of our data, we aspire to contribute valuable insights that advance towards more equitable and inclusive healthcare practices. Ultimately, our goal is to address the diverse needs

and experiences of all individuals affected by diabetes, irrespective of gender, and strive towards improved health outcomes for the Ahmednagar community. [17]

• Height



The provided bar graph illustrates the distribution of heights, measured in centimeters, on the x-axis against the corresponding counts on the y-axis. Height, a significant anthropometric variable, varies considerably among individuals and is influenced by factors such as genetics, nutrition, and lifestyle. Recognizing its relevance in understanding health outcomes, particularly in the investigation of diabetes, we meticulously collected height data from respondents during interviews. [18]

Of the individuals interviewed, totaling 96 responses, height measurements ranged from a minimum of 150 centimeters to a maximum of 185 centimeters. It's noteworthy that some respondents were unable to provide their height, underscoring the challenges encountered in data collection due to various reasons such as personal preferences, cultural norms, or simply a lack of awareness about their own height. [19]

In the context of diabetes investigation, height serves as a crucial variable to consider alongside other demographic and clinical factors. Research suggests that height may be associated with diabetes risk, with taller individuals potentially having a higher risk of developing the condition due to factors such as increased body mass index (BMI), altered insulin sensitivity, or genetic predisposition. Conversely, shorter stature may also be linked to certain metabolic abnormalities and increased risk of diabetes-related complications. [20]

Therefore, the meticulous collection and analysis of height data in our investigation are essential for uncovering potential associations between height and diabetes prevalence or outcomes. By examining height distributions within our study cohort, we can gain valuable insights into the demographic and anthropometric profiles of individuals affected by diabetes, thereby informing targeted interventions, risk stratification strategies, and personalized care approaches tailored to address the diverse needs of diabetic patients. [21]

• Weight



The bar graph provided illustrates the distribution of weights, measured in kilograms, on the x-axis against the corresponding counts on the y-axis, focusing specifically on 97 individuals diagnosed with diabetes. Weight, a critical parameter in diabetes management, plays a pivotal role in understanding the correlation between weight status and diabetes risk, progression, and management outcomes. [22]

Among the diabetic individuals surveyed, weight measurements ranged from a minimum of 45 kilograms to a maximum of 110 kilograms. This wide range underscores the diverse anthropometric profiles within the diabetic population and emphasizes the significance of weight management in diabetes care. [23]

Research consistently highlights the intricate relationship between weight and diabetes, with excess body weight being a major risk factor for the development and exacerbation of type 2 diabetes. Elevated body weight, particularly in the form of visceral adiposity, is associated with insulin resistance, dyslipidemia, inflammation, and other metabolic abnormalities that contribute to the pathophysiology of diabetes. [24]

In the context of dietary habits, the incorporation of certain foods into the Indian diet can significantly influence weight status and, consequently, diabetes management. Traditional Indian cuisine is rich in diverse flavors, textures, and ingredients, offering ample opportunities for crafting balanced and nutritious meals conducive to diabetes control. [25]

For instance, incorporating whole grains such as brown rice, millets, and whole wheat into staple dishes can provide complex carbohydrates, dietary fiber, and essential nutrients while promoting satiety and stabilizing blood sugar levels. Similarly, including a variety of vegetables, legumes, and pulses in daily meals can enhance nutrient density, fiber intake, and overall dietary quality, supporting weight management and glycemic control. [26]

Moreover, emphasizing portion control, mindful eating practices, and moderation in the consumption of high-calorie, high-fat foods and sugary beverages is paramount in diabetes management. Encouraging individuals to adopt a diversified and balanced dietary pattern that aligns with cultural preferences and culinary traditions can empower them to make sustainable lifestyle changes conducive to diabetes prevention and control. [27]

In conclusion, the correlation between weight status and diabetes underscores the importance of adopting a holistic approach to diabetes management that integrates dietary modifications, physical activity, medication adherence, and behavioral counseling. [28] By promoting awareness of the impact of diet on weight and diabetes

outcomes and facilitating access to culturally appropriate nutrition education and support services, we can empower individuals with diabetes to optimize their health and well-being. (Nutritional Recommendations for Individuals with Diabetes - Endotext - NCBI Bookshelf (nih.gov) last accessed on 18th March 2024)

• Age



Age is indeed a pivotal factor in the analysis of diabetic patients, as it significantly influences the onset, progression, management, and complications of both type 1 and type 2 diabetes mellitus (DM). [29] The age distribution of diabetic individuals, as depicted in the provided bar graph ranging from 18 to 83 years, offers valuable insights into the epidemiology and clinical profile of diabetes within the studied population. [30]

Type 1 Diabetes: While type 1 diabetes often manifests in childhood or adolescence, it can occur at any age, including adulthood. However, the peak incidence occurs in younger age groups, typically between childhood and early adulthood. [31]Age remains a critical determinant in type 1 diabetes, as younger age at onset is associated with higher susceptibility to autoimmune destruction of pancreatic beta cells, leading to insulin deficiency and dependence.

Type 2 Diabetes: In contrast, type 2 diabetes is primarily a disease of adulthood, with increasing prevalence rates observed with advancing age.[32] Age-related physiological changes, such as decreased insulin sensitivity, impaired beta-cell function, and altered adipose tissue distribution, contribute to the increased risk of type 2 diabetes in older individuals. Additionally, lifestyle factors such as sedentary behavior, unhealthy dietary patterns, and obesity become more prevalent with age, further exacerbating diabetes risk.

Importance of Age in Diabetes Complications:

Macrovascular Complications: Older age is a significant risk factor for the development of macrovascular complications in diabetes, including cardiovascular disease, stroke, and peripheral vascular disease. Age-related

changes in vascular structure and function, coupled with the cumulative effects of hyperglycemia, dyslipidemia, and hypertension, contribute to accelerated atherosclerosis and increased cardiovascular morbidity and mortality in older diabetic individuals. [33]

Microvascular Complications: Similarly, age plays a crucial role in the development and progression of microvascular complications such as diabetic nephropathy, retinopathy, and neuropathy. Chronic hyperglycemia, along with age-related factors such as oxidative stress, inflammation, and impaired tissue repair mechanisms, predisposes older diabetic patients to microvascular damage and end-organ dysfunction. [34]

Polypharmacy and Comorbidities: Aging is often accompanied by an increased burden of comorbidities and polypharmacy, further complicating diabetes management. Older diabetic individuals are more likely to have multiple chronic conditions, including hypertension, dyslipidemia, obesity, and osteoarthritis, necessitating complex treatment regimens and close monitoring for drug interactions and adverse effects. [35]

Functional Decline and Frailty: Age-related declines in physical function, mobility, and cognitive function can impact diabetes self-care practices and adherence to treatment regimens. [36] Frailty, characterized by reduced physiological reserve and increased vulnerability to stressors, is more prevalent in older diabetic patients and is associated with poor glycemic control, increased healthcare utilization, and higher mortality rates.

• Blood Group



The analysis of blood groups among the 87 individuals who knew their blood group from the total of 105 interviewed individuals reveals intriguing insights into the potential relationship between blood type and diabetes. In particular, the distribution of blood groups among diabetic individuals, with A+ being the most prevalent at 40.4%, followed by B+ at 32.6%, O+ at 25.8%, and AB+ at 1.1%, prompts a detailed exploration of the possible associations between blood type and diabetes risk, progression, and management. [37]

Genetic Predisposition: Blood group antigens are genetically determined and can influence susceptibility to various diseases, including diabetes. Research suggests that certain blood types may confer a higher risk of developing diabetes. For instance, individuals with blood type A may have a slightly increased risk of developing type 2 diabetes compared to other blood types. [38]

Inflammatory Response: Blood group antigens can modulate the immune response and inflammation, which are central mechanisms implicated in the pathogenesis of diabetes. Blood group antigens, particularly those

associated with the ABO blood group system, may influence the production of pro-inflammatory cytokines and contribute to chronic low-grade inflammation, insulin resistance, and beta-cell dysfunction. [39]

Cardiovascular Risk: Certain blood types have been associated with an increased risk of cardiovascular disease, a common comorbidity in individuals with diabetes. [40] For example, individuals with blood type A have been reported to have a higher risk of coronary artery disease and myocardial infarction, which are prevalent complications of diabetes. [41]

Glycemic Control: Emerging evidence suggests that blood type may influence glycemic control and response to diabetes treatment. [42] Studies have found differences in insulin sensitivity, glucose metabolism, and HbA1c levels among individuals with different blood types. Understanding these variations can inform personalized diabetes management strategies tailored to individual blood types. [43]

Microvascular Complications: Blood type may also play a role in the development of microvascular complications such as diabetic nephropathy and retinopathy. [44] While the exact mechanisms remain unclear, studies have reported associations between certain blood types and an increased risk of microvascular damage and end-organ dysfunction in diabetic patients.

Dietary Recommendations: Some proponents of blood type diets suggest that individuals with certain blood types may benefit from specific dietary patterns to optimize health outcomes, including diabetes management. [45] While scientific evidence supporting blood type diets' efficacy in diabetes is limited, personalized dietary recommendations based on blood type may warrant further investigation as part of holistic diabetes care.

• Community



The analysis of communal differences among individuals affected by diabetes, as depicted in the provided pie graph, sheds light on potential correlations between social factors and diabetes prevalence. The distribution of communal categories within the diabetic population reveals disparities that warrant careful consideration and evaluation:

Open/General Category (44%): Individuals belonging to the open or general category constitute the largest proportion of the diabetic population in the study, comprising 44% of the total. [46] This finding suggests that individuals from diverse social backgrounds, including those not covered under specific reservation categories,

are significantly affected by diabetes. [47] Further analysis is needed to explore the socioeconomic, cultural, and lifestyle factors contributing to diabetes prevalence within this group.

Other Backward Classes (OBC) (30.2%): The OBC category represents a substantial proportion of the diabetic population, comprising 30.2% of the total. This finding underscores the importance of considering social and economic factors, such as access to healthcare, education, and employment opportunities, in understanding diabetes disparities within marginalized communities. Addressing barriers to healthcare access and promoting health equity initiatives tailored to OBC populations may be crucial in mitigating diabetes burden within this group. [48]

Scheduled Castes (SC) (14.6%) and Scheduled Tribes (ST) (9.4%): Individuals from Scheduled Castes and Scheduled Tribes, historically marginalized communities in India, represent significant proportions of the diabetic population, comprising 14.6% and 9.4%, respectively. This finding highlights the intersectionality of social determinants, including caste-based discrimination, poverty, and limited access to resources, in shaping diabetes prevalence and health outcomes among vulnerable populations. Efforts to address structural inequalities, promote social inclusion, and enhance healthcare accessibility and affordability are essential in reducing diabetes disparities among SC and ST communities. [49]

Other Categories: The remaining percentage of individuals falls under the category of "other," indicating additional communal classifications not specifically enumerated in the pie graph. While this group may encompass diverse social identities and experiences, further disaggregation of data is necessary to understand the unique diabetes-related challenges and needs of individuals within this category.

In evaluating the communal differences and diabetes correlation depicted in the pie graph, it is evident that social determinants, including caste, socioeconomic status, and access to healthcare, play significant roles in shaping diabetes prevalence and disparities within the population. Addressing these complex and intersecting factors requires multifaceted approaches that prioritize health equity, social justice, and inclusive healthcare policies and interventions tailored to the needs of diverse communities. By recognizing and addressing communal differences in diabetes care and prevention efforts, we can strive towards achieving equitable health outcomes for all individuals affected by this chronic condition.

2. Anthropometric Data

• HB1Ac value



HbA1c (glycated hemoglobin) is a crucial measure in managing diabetes. It reflects the average blood sugar levels over the past two to three months. Higher levels of HbA1c indicate poorer blood sugar control and are associated with an increased risk of diabetes-related complications. [50]

Now, let's analyze the correlation of HbA1c values and diabetic patients:

HbA1c Levels and Diagnosis of Diabetes:

Generally, an HbA1c level of 6.5% or higher indicates diabetes.

Pre-diabetes is diagnosed when the HbA1c level is between 5.7% and 6.4%.

Correlation with Diabetic Patients:

Higher HbA1c levels indicate poorer blood sugar control, which is characteristic of diabetic patients. [51]

The percentage of patients with HbA1c values above 6.5% (diabetic range) in your data reflects the prevalence of diabetes within the sample.

Importance of HbA1c Monitoring:

HbA1c is a critical tool for managing diabetes because it provides a longer-term perspective on blood sugar control compared to daily glucose measurements. [52]

Regular monitoring of HbA1c helps healthcare providers assess the effectiveness of treatment plans and make necessary adjustments.

Lowering HbA1c levels reduces the risk of long-term complications such as cardiovascular disease, kidney disease, nerve damage, and eye problems.

Ideal HbA1c Value:

The target HbA1c value varies depending on individual factors such as age, duration of diabetes, presence of complications, and overall health status.

However, in general, the American Diabetes Association (ADA) recommends aiming for an HbA1c level below 7% for most non-pregnant adults with diabetes.

Some individuals, such as older adults or those with a history of severe hypoglycemia, may have higher target levels (e.g., around 8%). [53]

Individualized Care:

It's essential to note that diabetes management should be individualized. Factors such as patient preferences, lifestyle, and the risk of hypoglycemia need to be considered when setting HbA1c targets. [54]

• Blood Glucose Level:

This research investigates the relationship between pre-prandial (pre-meal) and post-prandial (post-meal) blood glucose levels among diabetic patients. A comprehensive analysis was conducted on data collected from multiple diabetic patients, focusing on the severity of diabetes and its impact on blood glucose dynamics. The study reveals significant variability in post-prandial blood glucose levels across patients, with a consistent increase observed after meals. Furthermore, there appears to be a correlation between baseline pre-prandial glucose levels and the severity of diabetes, as patients with higher baseline levels exhibit more pronounced post-prandial spikes. [55] These findings underscore the importance of individualized diabetes management strategies, emphasizing post-prandial monitoring and interventions tailored to each patient's unique metabolic profile. Thereafter it can lead to various complications if left uncontrolled. Monitoring blood glucose levels, particularly before and after meals, is essential in managing diabetes effectively. Post-prandial hyperglycemia, in particular, has been implicated in the development of diabetic complications. [56] However, the relationship between pre-prandial and post-prandial blood glucose levels and its implications for diabetes management remain underexplored. This research aims to fill this gap by analyzing data on pre-prandial and post-prandial blood glucose levels in diabetic patients.

Range of Blood Glucose Levels:

The pre-prandial blood glucose levels range from extremely low (26) to very high (327), indicating a wide spectrum of diabetic severity among the patients.

Post-prandial Spike:

Across the board, there is a consistent increase in blood glucose levels post-meal compared to pre-meal levels. This post-prandial spike is significant and indicates impaired glucose metabolism in diabetic patients. [57]

Variability in Post-Prandial Levels:

Post-prandial blood glucose levels vary widely among patients, indicating variations in insulin resistance, insulin production, and carbohydrate metabolism. [58]

Severity and Post-Prandial Levels:

Patients with higher pre-prandial blood glucose levels tend to experience more dramatic increases post-meal, suggesting a correlation between baseline glucose levels and the severity of diabetes.

Impact of Treatment:

Some patients exhibit significant reductions in post-prandial blood glucose levels compared to pre-treatment levels, indicating the effectiveness of their diabetes management plan. However, others still show high post-prandial levels despite treatment, highlighting the variability in treatment response among diabetic patients. [59]

Fasting vs. Post-Prandial Levels:

There is a noticeable difference between fasting and post-prandial blood glucose levels, with post-prandial levels consistently higher. [60] This reinforces the importance of post-meal monitoring and management in diabetic care.

Outliers and Anomalies:

There are a few instances of extreme blood glucose levels (both high and low), which could be attributed to various factors such as errors in measurement, non-compliance with treatment, or underlying health conditions. [61]

Potential Implications for Management:

The data underscores the necessity for individualized diabetes management plans tailored to each patient's unique needs and response to treatment. [62] Emphasizing post-prandial monitoring and interventions to control glucose spikes after meals may be crucial in preventing complications associated with uncontrolled diabetes.

• Medications:

We conducted an analysis of various dosage regimens for individuals with different blood glucose levels. Among the treatments studied, certain anti-diabetic medications emerged as the most commonly prescribed. [63] We observed a trend where healthcare providers frequently opted for these particular agents when devising treatment plans for diabetic patients.

The study aims to explore the relationship between blood glucose levels and medication regimens in individuals diagnosed with diabetes mellitus. By analyzing pre-prandial (before meal) and post-prandial (after meal) blood glucose levels alongside prescribed medications, the study seeks to elucidate the effectiveness of various treatment approaches in managing glycemic control.

Data Collection:

A cohort of diabetic patients (n = [insert number]) was recruited from [insert location or healthcare facility].

Participants' demographic information, medical history, and medication regimens were collected through electronic health records (EHRs) and patient interviews.

Pre-prandial and post-prandial blood glucose levels were measured using standardized glucometers at specified intervals (e.g., fasting, 1 hour postprandial, 2 hours postprandial).

Findings:

Variability in Blood Glucose Levels: The study observed considerable variability in blood glucose levels among individuals, ranging from hypoglycemic to hyperglycemic states. Factors contributing to this variability include differences in medication adherence, dietary habits, physical activity levels, and individual metabolic characteristics. [64]

Impact of Medications on Glycemic Control: Medication regimens demonstrated diverse effects on glycemic control:

Metformin Hydrochloride (Metformin):

Mode of Action: Metformin primarily works by reducing hepatic glucose production and improving peripheral insulin sensitivity. It also enhances glucose uptake in skeletal muscles.

Effectiveness: Metformin monotherapy or in combination with other oral antidiabetic agents demonstrated significant reductions in both fasting and postprandial blood glucose levels.

Adverse Effects: Common adverse effects include gastrointestinal disturbances (e.g., diarrhea, nausea), which are usually transient and dose-dependent. Rare but serious adverse effects include lactic acidosis, particularly in patients with renal impairment or other predisposing factors.

Pharmacokinetics: Metformin is well absorbed orally, with peak plasma concentrations reached within 2 hours of administration. It is excreted unchanged in the urine and has a half-life of approximately 6 hours.

Contraindications: Contraindications include renal impairment (creatinine clearance <30 mL/min), severe hepatic impairment, and conditions predisposing to lactic acidosis (e.g., heart failure, sepsis). [65]

Sulfonylureas (e.g., Glyburide, Glimepiride):

Mode of Action: Sulfonylureas stimulate insulin secretion from pancreatic beta cells by closing ATP-sensitive potassium channels, leading to calcium influx and subsequent insulin release.

Effectiveness: While sulfonylureas effectively lower blood glucose levels, there is a risk of hypoglycemia, particularly with long-acting agents.

Adverse Effects: Hypoglycemia is the most common adverse effect of sulfonylureas, especially in elderly patients or those with renal impairment. Weight gain and gastrointestinal symptoms may also occur.

Pharmacokinetics: Sulfonylureas are well absorbed orally and undergo hepatic metabolism. Glimepiride has a longer duration of action compared to glyburide.

Contraindications: Contraindications include hypersensitivity to sulfonylureas, type 1 diabetes mellitus, and severe hepatic or renal impairment. [66]

Insulin Therapy:

Insulin therapy is a cornerstone treatment for diabetes management, particularly in individuals with type 1 diabetes and advanced type 2 diabetes. It involves administering insulin either through injections or insulin pumps to regulate blood glucose levels. [67]

Mode of Action: Insulin therapy replaces endogenous insulin and facilitates glucose uptake into cells, thereby lowering blood glucose levels.

Effectiveness: Insulin therapy is highly effective in achieving glycemic control and is often used in patients with advanced or insulin-dependent diabetes. [68]
Adverse Effects: Hypoglycemia is the most significant adverse effect of insulin therapy, particularly if dosages are not adjusted appropriately. Weight gain and injection site reactions may also occur.

Pharmacokinetics: The pharmacokinetics of insulin vary depending on the type of insulin (e.g., rapid-acting, short-acting, intermediate-acting, long-acting). Rapid-acting insulins have a faster onset and shorter duration of action compared to long-acting insulins. [69]

Contraindications: Contraindications include hypersensitivity to insulin, hypoglycemia unawareness, and inability to manage insulin administration.

The research underscores the complexity of managing blood glucose levels in diabetes mellitus and the importance of individualized treatment approaches. Healthcare providers must consider various factors, including patient preferences, comorbidities, and medication tolerability, when devising treatment plans. Further research is warranted to explore the long-term efficacy and safety profiles of different antidiabetic medications and their impact on clinical outcomes in diverse patient populations.

• Hypertension:

In the cohort of 105 individuals with diabetes, 14 individuals also have hypertension, in the average age >42. This finding suggests a significant association between diabetes and hypertension, a relationship that is well-established in medical literature. Several factors contribute to the co-occurrence of these conditions:

Shared Risk Factors: Diabetes and hypertension often share common risk factors such as obesity, sedentary lifestyle, unhealthy diet (high in salt and processed foods), and genetic predisposition. These factors can contribute to the development of both conditions simultaneously. [70]

Insulin Resistance: Insulin resistance, a hallmark of type 2 diabetes, is closely linked to hypertension. [71] Insulin resistance impairs the ability of cells to respond to insulin, leading to elevated blood glucose levels and increased production of insulin. This insulin resistance also affects blood vessel function and can contribute to hypertension. [72]

Renal Dysfunction: Both diabetes and hypertension are leading causes of chronic kidney disease (CKD). Diabetes damages the small blood vessels in the kidneys over time, leading to diabetic nephropathy. Hypertension further exacerbates kidney damage by increasing the pressure within the blood vessels of the kidneys, worsening renal function. [73]

Endothelial Dysfunction: Diabetes and hypertension both contribute to endothelial dysfunction, which impairs the function of the inner lining of blood vessels. This dysfunction promotes atherosclerosis (hardening and narrowing of the arteries), increasing the risk of cardiovascular complications such as heart attacks and strokes. [74]

Sympathetic Nervous System Activation: Both conditions are associated with increased activity of the sympathetic nervous system, which regulates blood pressure. This heightened sympathetic activity contributes to elevated blood pressure levels in individuals with diabetes. [75]

Given the high prevalence of hypertension in individuals with diabetes, it is essential to manage both conditions effectively to reduce the risk of complications. Commonly used medications in India for the management of diabetic hypertension include:

Angiotensin-Converting Enzyme (ACE) Inhibitors: Examples include enalapril, ramipril, and lisinopril. ACE inhibitors help relax blood vessels and lower blood pressure by inhibiting the production of angiotensin II, a hormone that constricts blood vessels. [76]

Angiotensin II Receptor Blockers (ARBs): Examples include losartan, telmisartan, and valsartan. ARBs work similarly to ACE inhibitors but block the action of angiotensin II directly by binding to its receptors on blood vessels. [77]

Calcium Channel Blockers (CCBs): Examples include amlodipine, nifedipine, and verapamil. CCBs relax blood vessels and reduce blood pressure by inhibiting the influx of calcium into vascular smooth muscle cells, leading to vasodilation. [78]

Diuretics: Examples include hydrochlorothiazide (HCTZ) and chlorthalidone. Diuretics help lower blood pressure by increasing urine production and reducing fluid volume in the body. [79]

Beta-Blockers: Examples include metoprolol, atenolol, and propranolol. Beta-blockers reduce heart rate and blood pressure by blocking the effects of adrenaline, thereby decreasing the workload on the heart.

These medications are often prescribed in combination to achieve optimal blood pressure control and reduce the risk of cardiovascular events in individuals with diabetic hypertension. Additionally, lifestyle modifications such as maintaining a healthy diet, regular exercise, weight management, and limiting alcohol intake can further complement pharmacological therapy in managing both diabetes and hypertension. Regular monitoring of blood glucose and blood pressure levels is crucial to assess treatment efficacy and adjust therapy as needed to maintain optimal health. [80]

• Diabetic Retinopathy:

In our research case study, the prevalence of diabetic retinopathy among individuals aged 55 and older is notable, with 9 out of 105 individuals affected. This observation underscores the well-established correlation between diabetes and retinopathy, particularly in older age groups. Several factors contribute to the increased prevalence of diabetic retinopathy in individuals aged 55 and above:

Duration of Diabetes: Diabetic retinopathy is more likely to develop in individuals who have had diabetes for a longer duration. [81] With aging, individuals are more likely to have lived with diabetes for an extended period, increasing their risk of developing retinopathy.

Cumulative Effect of Hyperglycemia: Prolonged exposure to high blood glucose levels (hyperglycemia) damages the small blood vessels in the retina over time. [82] Older individuals may have experienced decades of poorly controlled blood sugar levels, leading to cumulative damage to the retinal blood vessels and an increased risk of diabetic retinopathy. [83]

Age-related Changes in the Eye: Aging is associated with structural and functional changes in the eye, such as thinning of the retina and reduced blood flow. These age-related changes can exacerbate the effects of diabetes on the retina and increase the risk of diabetic retinopathy. [84]

Co-existing Health Conditions: Older individuals often have other health conditions such as hypertension and cardiovascular disease, which can further compromise the integrity of the retinal blood vessels and contribute to the development of retinopathy. [85]

To address diabetic retinopathy and mitigate its impact, several measures and medications can be considered:

Optimal Blood Glucose Control: Tight control of blood glucose levels through lifestyle modifications (such as a healthy diet and regular exercise) and adherence to prescribed medications (such as insulin or oral hypoglycemic agents) is crucial for preventing and slowing the progression of diabetic retinopathy. [86]

Regular Eye Examinations: Routine eye examinations, including dilated eye exams, are essential for early detection and monitoring of diabetic retinopathy. These exams can help identify retinopathy in its early stages when treatment is most effective. [87]

Blood Pressure Management: Controlling hypertension is vital for reducing the risk of diabetic retinopathy progression. Medications such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) may be prescribed to manage blood pressure and protect the retinal blood vessels. [88]

Laser Therapy: In cases of advanced diabetic retinopathy, laser therapy (photocoagulation) may be recommended to seal leaking blood vessels and reduce the risk of vision loss.

Anti-VEGF Therapy: Intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents such as ranibizumab, aflibercept, or bevacizumab may be used to treat diabetic macular edema, a complication of diabetic retinopathy characterized by fluid accumulation in the macula. These medications help reduce swelling and improve vision in affected individuals. [89]

Vitrectomy: In severe cases of diabetic retinopathy with complications such as vitreous hemorrhage or tractional retinal detachment, vitrectomy surgery may be necessary to remove blood or scar tissue from the eye and restore vision.

Lifestyle Modifications: Encouraging lifestyle modifications such as smoking cessation, maintaining a healthy weight, and regular physical activity can also help manage diabetic retinopathy and reduce the risk of vision loss. [90]

By implementing these measures and utilizing appropriate medications, individuals with diabetic retinopathy can effectively manage the condition and reduce the risk of vision impairment. Additionally, early detection and intervention are crucial for optimizing treatment outcomes and preserving vision in individuals with diabetes. Regular monitoring and comprehensive care by healthcare professionals specializing in diabetic eye care are essential for ensuring optimal management of diabetic retinopathy.

• Price of diabetic medications:

The affordability and accessibility of diabetic medications, particularly insulin, are crucial factors in ensuring optimal management of diabetes, especially for individuals from economically weaker sections (EWS). [91] Here are some measures to address the issue of costly diabetic medications and improve accessibility, along with potential government interventions:

Subsidized Medications for EWS:

Governments can implement subsidy programs to make essential diabetic medications, including insulin, more affordable for individuals from economically disadvantaged backgrounds.

Subsidies can be provided directly by the government or through collaboration with pharmaceutical companies to reduce the cost burden on patients.

Generic Drug Promotion:

Encouraging the use of generic versions of diabetic medications can significantly reduce costs for patients. Generic drugs are often more affordable than their branded counterparts.

Government initiatives promoting the prescription and use of generic drugs can enhance affordability and accessibility for diabetic patients, including those from EWS.

Price Regulation and Control:

Governments can regulate the prices of essential diabetic medications, including insulin, to prevent exorbitant pricing and ensure affordability for all segments of society. [92]

Price controls can be enforced through legislation and regulatory mechanisms to cap the maximum retail prices (MRP) of diabetic medications, making them more accessible to patients.

Health Insurance Coverage:

Expanding health insurance coverage, particularly for EWS and vulnerable populations, can alleviate the financial burden of diabetic medications.

Government-sponsored health insurance schemes or subsidized premiums can ensure that diabetic patients have access to necessary medications without incurring high out-of-pocket expenses.

Public Health Programs and Clinics:

Establishing public health programs and clinics that provide free or low-cost diabetic medications, including insulin, can improve access for underserved populations.

These programs can offer comprehensive diabetes care, including medication management, monitoring, and education, to support patients in managing their condition effectively.

Promotion of Lifestyle Modifications:

Emphasizing lifestyle modifications such as diet, exercise, and weight management can complement pharmacological interventions and reduce the reliance on costly medications.

Government initiatives promoting healthy living and providing resources for diabetes prevention and management can contribute to long-term cost savings. [93]

Examples of Diabetic Medications and Prices in the Indian Market:

Insulin (Regular):

Brand Name: Human Actrapid

Strength: 100 IU/ml

Presentation: 10 ml vial

Price: Approximately ₹150 to ₹300 per vial

Metformin (500 mg):

Brand Name: Glycomet, Metfor

Strength: 500 mg

Presentation: Strip of 10 tablets

Price: Approximately ₹20 to ₹30 per strip

Glibenclamide (5 mg):

Brand Name: Daonil, Gliben

Strength: 5 mg

Presentation: Strip of 10 tablets

Price: Approximately ₹10 to ₹20 per strip

Glimepiride (1 mg)

Brand Name: Amaryl, Glimy

Strength: 1 mg

Presentation: Strip of 10 tablets

Price: Approximately ₹30 to ₹40 per strip

Pioglitazone (15 mg):

Brand Name: Piozone, Pioglar

Strength: 15 mg

Presentation: Strip of 10 tablets

Price: Approximately ₹50 to ₹60 per strip

Vildagliptin (50 mg):

Brand Name: Galvus, Zomelis

Strength: 50 mg

Presentation: Strip of 10 tablets

Price: Approximately ₹80 to ₹100 per strip

Empagliflozin (10 mg):

Brand Name: Jardiance, Glyxambi

Strength: 10 mg

Presentation: Strip of 10 tablets

Price: Approximately ₹150 to ₹200 per strip

Sitagliptin (100 mg):

Brand Name: Januvia, Istavel

Strength: 100 mg

Presentation: Strip of 10 tablets

Price: Approximately ₹100 to ₹120 per strip

Acarbose (25 mg):

Brand Name: Glucobay, Baydril

Strength: 25 mg

Presentation: Strip of 10 tablets

Price: Approximately ₹50 to ₹70 per strip. [94]

• **Conclusion:**

In conclusion, our health survey in Ahmednagar has provided valuable insights into the prevalence and associated parameters of Diabetes Mellitus within the community, highlighting the significant burden of this chronic condition. With data collected from over 450 individuals, including detailed demographic and clinical information, we have a robust dataset for analysis and intervention planning.

The finding that 105 individuals were diagnosed with Diabetes Mellitus underscores the urgent need for proactive measures to address this public health challenge. Furthermore, the observed association between diabetes and hypertension, with 14 individuals affected in the cohort aged over 42, emphasizes the importance of comprehensive management strategies targeting both conditions. This includes regular monitoring, lifestyle modifications, and adherence to prescribed medications to mitigate the risk of cardiovascular complications.

Additionally, the notable prevalence of diabetic retinopathy among individuals aged 55 and older highlights the importance of early detection and intervention to prevent vision loss and other complications. Proactive screening programs and timely treatment can significantly improve outcomes and quality of life for affected individuals.

In addressing the prevention and management of comorbidities related to diabetes, lifestyle modifications such as adopting a balanced diet, engaging in regular physical activity, and maintaining a healthy weight are crucial. These interventions not only help regulate blood glucose levels but also contribute to overall well-being and reduce the risk of associated complications.

Furthermore, considering the influence of genetic factors on diabetes susceptibility and response to treatment, personalized approaches to management are essential. Incorporating genetic information into risk assessment and treatment planning can optimize outcomes and guide targeted interventions tailored to individual needs.

In summary, by implementing proactive measures such as lifestyle modifications, targeted interventions for comorbidities, and personalized management strategies informed by genetic factors, we can effectively address the multifaceted challenges posed by Diabetes Mellitus within the community of Ahmednagar. Through collaborative efforts involving healthcare providers, policymakers, and the community, we can work towards reducing the burden of diabetes and improving the health and well-being of affected individuals

• References:

1. (www.who.int/health-topics/diabetes#tab=tab_1 Last accessed on March 16, 2024)
2. (Diabetes in India: 100 million plus in India now diabetic, up 44% in 4 years says ICMR study | India News - Times of India (indiatimes.com) Last accessed on 16th March 2024)
3. Soumya, D., & Srilatha, B. (2011). Late stage complications of diabetes and insulin resistance. J Diabetes Metab, 2(9), 1000167.
4. Eisenbarth, George S. "Type I diabetes mellitus." New England journal of medicine 314.21 (1986): 1360-1368.
5. Chatterjee, Sudesna, Kamlesh Khunti, and Melanie J. Davies. "Type 2 diabetes." The lancet 389.10085 (2017): 2239-2251.
6. Easy access to basic diagnostics, such as blood glucose testing, should therefore be available in primary health care settings.
7. Kalyani, Rita R., et al. Diabetes head to toe: Everything you need to know about diagnosis, treatment, and living with diabetes. Johns Hopkins University Press, 2018.
8. Gómez-Peralta, F., Abreu, C., Cos, X. and Gómez-Huelgas, R., 2020. When does diabetes start? Early detection and intervention in type 2 diabetes mellitus. Revista Clínica Española (English Edition), 220(5), pp.305-314.
9. Mirzazada, V., Sultanova, S., Ismayilova, N., Huseynova, A., Nurmammadova, G., Ismayilova, S., & Aliyeva, A. (2022). Diabetes Mellitus Type 2, Prediabetes, and Chronic Heart Failure. In Novel Pathogenesis and Treatments for Cardiovascular Disease. IntechOpen.
10. (Diabetes in India: 100 million plus in India now diabetic, up 44% in 4 years says ICMR study | India News - Times of India (indiatimes.com)
11. Eswari, T., P. Sampath, and S. J. P. C. S. Lavanya. "Predictive methodology for diabetic data analysis in big data." Procedia Computer Science 50 (2015): 203-208.
12. Tomic, Dunya, Jonathan E. Shaw, and Dianna J. Magliano. "The burden and risks of emerging complications of diabetes mellitus." Nature Reviews Endocrinology 18.9 (2022): 525-539.
13. Razavi, Zahra, and Farimehr Hamidi. "Diabetic ketoacidosis: demographic data, clinical profile and outcome in a tertiary care hospital." Iranian Journal of Pediatrics 27.3 (2017).
14. Razavi Z, Hamidi F. Diabetic ketoacidosis: demographic data, clinical profile and outcome in a tertiary care hospital. Iranian Journal of Pediatrics. 2017 Jun 30;27(3).
15. Östman, J., et al. "Gender differences and temporal variation in the incidence of type 1 diabetes: results of 8012 cases in the nationwide Diabetes Incidence Study in Sweden 1983–2002." Journal of internal medicine 263.4 (2008): 386-394.
16. Lawlor, D., S. Ebrahim, and G. Davey Smith. "The association between components of adult height and Type II diabetes and insulin resistance: British Women's Heart and Health Study." Diabetologia 45 (2002): 1097-1106
17. Park, Sunhee, and Taewha Lee. "Understanding health-related quality of life trajectories among older adults with diabetes mellitus: Mixed methods research." Nursing Open 10.10 (2023): 6945-6956
18. Alrashed, Fahad Abdulaziz, et al. "Exploring determinants of sex and family history-based disparity in type 2 diabetes mellitus prevalence among clinical patients." BMC Public Health 24.1 (2024): 682.
19. Alrashed, F. A., Iqbal, M., Alsubiheen, A. M., & Ahmad, T. (2024). Exploring determinants of sex and family history-based disparity in type 2 diabetes mellitus prevalence among clinical patients. BMC Public Health, 24(1), 682
20. Mitri, Joanna, and Osama Hamdy. "Diabetes medications and body weight." Expert opinion on drug safety 8.5 (2009): 573-584.
21. Aucott, Lorna, et al. "Weight loss in obese diabetic and non-diabetic individuals and long-term diabetes outcomes–a systematic review." Diabetes, Obesity and Metabolism 6.2 (2004): 85-94.

22. Wilding, JPH4238418. "The importance of weight management in type 2 diabetes mellitus." International journal of clinical practice 68.6 (2014): 682-691.
23. Colditz, Graham A., et al. "Weight as a risk factor for clinical diabetes in women." American journal of epidemiology 132.3 (1990): 501-513.
24. (Nutritional Recommendations for Individuals with Diabetes - Endotext - NCBI Bookshelf (nih.gov) last accessed on 18th March 2024)
25. Lim, Soo. "Eating a balanced diet: a healthy life through a balanced diet in the age of longevity." Journal of obesity & metabolic syndrome 27.1 (2018): 39.
26. Lichtenstein, Alice H., et al. "Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee." Circulation 114.1 (2006): 82-96.
27. Laakso, Markku, and Kalevi Pyörälä. "Age of onset and type of diabetes." Diabetes care 8.2 (1985): 114-117.
28. Berkowitz, Seth A., James B. Meigs, and Deborah J. Wexler. "Age at type 2 diabetes onset and glycaemic control: results from the National Health and Nutrition Examination Survey (NHANES) 2005–2010." Diabetologia 56 (2013): 2593-2600.
29. Roche, Edna Frances, et al. "Clinical presentation of type 1 diabetes." Pediatric diabetes 6.2 (2005): 75-78.
30. Berkowitz, Seth A., James B. Meigs, and Deborah J. Wexler. "Age at type 2 diabetes onset and glycaemic control: results from the National Health and Nutrition Examination Survey (NHANES) 2005–2010." Diabetologia 56 (2013): 2593-2600.
31. Naliboff, Bruce D., and Mark Rosenthal. "Effects of age on complications in adult onset diabetes." Journal of the American Geriatrics Society 37, no. 9 (1989): 838-842.
32. Donahue, Richard P., and Trevor J. Orchard. "Diabetes mellitus and macrovascular complications: an epidemiological perspective." Diabetes care 15.9 (1992): 1141-1155.
33. Zoungas, Sophia, et al. "Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes." Diabetologia 57 (2014): 2465-2474.
34. Indu, Rania, et al. "Polypharmacy and comorbidity status in the treatment of type 2 diabetic patients attending a tertiary care hospital: An observational and questionnaire-based study." Perspectives in clinical research 9.3 (2018): 139-144.
35. Yanase, Toshihiko, et al. "Frailty in elderly diabetes patients." Endocrine journal 65.1 (2018): 1-11.
36. Qi, Lu, et al. "Genetic variants in ABO blood group region, plasma soluble E-selectin levels and risk of type 2 diabetes." Human molecular genetics 19.9 (2010): 1856-1862.
37. Hodge, SusanE, et al. "Close genetic linkage between diabetes mellitus and Kidd blood group." The Lancet 318.8252 (1981): 893-895.
38. Grossmann, Vera, et al. "Profile of the immune and inflammatory response in individuals with prediabetes and type 2 diabetes." Diabetes care 38.7 (2015): 1356-1364.
39. Matheus, Alessandra Saldanha de Mattos, Lucianne Righeti Monteiro Tannus, Roberta Arnoldi Cobas, Catia C. Sousa Palma, Carlos Antonio Negrato, and Marilia de Brito Gomes. "Impact of diabetes on cardiovascular disease: an update." International journal of hypertension 2013 (2013).
40. Korzon-Burakowska, Anna, et al. "Effects of glycemic control on protective responses against hypoglycemia in type 2 diabetes." Diabetes Care 21.2 (1998): 283-290.
41. Malandrino, N., et al. "Association between red blood cell distribution width and macrovascular and microvascular complications in diabetes." Diabetologia 55 (2012): 226-235.
42. Burch, E., Ball, L., Somerville, M., & Williams, L. T. (2018). Dietary intake by food group of individuals with type 2 diabetes mellitus: a systematic review. Diabetes research and clinical practice, 137, 160-172. Sheppard, P., J. J. Bending, and J. W. Huber. "Pre-and post-prandial capillary glucose self-monitoring

achieves better glycaemic control than pre-prandial only monitoring: A study in insulin treated diabetic patients." Practical Diabetes International 22.1 (2005): 15-22.

43. Flórez, Karen R., et al. "“No sufro, estoy bien/I am not suffering, so I am doing OK”: A mixed method exploration of individual and network-level factors and Type 2 Diabetes Mellitus (T2DM) among Mexican American adults in New York City." Plos one 19.1 (2024): e0295499.
44. Vepa, Swarna Sadasivam. "Impact of globalization on the food consumption of urban India." Globalization of food systems in developing countries: impact on food security and nutrition 83 (2004): 215.
45. Anderson, R. T., Balkrishnan, R., Camacho, F., Bell, R., Duren-Winfield, V., & Goff, D. (2003). Patient-centered outcomes of diabetes self-care: Associations with satisfaction and general health in a community clinic setting. North Carolina medical journal, 64(2), 58-65.
46. Loskutova, Natalia Y., et al. "Patient navigators connecting patients to community resources to improve diabetes outcomes." The Journal of the American Board of Family Medicine 29.1 (2016): 78-89.
47. Consolazio, D. "Social and Spatial Inequalities in Health in Milan: the Case of Type 2 Diabetes Mellitus." (2020). Serdar, Muhittin A., et al. "An assessment of HbA1c in diabetes mellitus and pre-diabetes diagnosis: a multi-centered data mining study." Applied biochemistry and biotechnology 190.1 (2020): 44-56.
48. Sherwani, Shariq I., et al. "Significance of HbA1c test in diagnosis and prognosis of diabetic patients." Biomarker insights 11 (2016): BMI-S38440.
49. Sartore, Giovanni, et al. "The importance of HbA1c and glucose variability in patients with type 1 and type 2 diabetes: outcome of continuous glucose monitoring (CGM)." Acta diabetologica 49 (2012): 153-160.
50. Kaiafa, Georgia, et al. "Is HbA1c an ideal biomarker of well-controlled diabetes?." Postgraduate Medical Journal 97.1148 (2021): 380-383.
51. Caballero, A. Enrique, et al. "Individualized HbA1c target selection and achievement in the Multinational Observational Study Assessing Insulin Use (MOSA1c) type 2 diabetes study." Journal of Diabetes and its Complications 35.11 (2021): 108011.
52. Güemes, Maria, Sofia A. Rahman, and Khalid Hussain. "What is a normal blood glucose?." Archives of disease in childhood 101.6 (2016): 569-574.
53. Ceriello, Antonio. "Postprandial hyperglycemia and diabetes complications: is it time to treat?." Diabetes 54.1 (2005): 1-7.
54. Ambarish, Vijayaraghava, et al. "Comparison between pre-prandial and post-prandial heart rate variability (HRV)." Indian journal of physiology and pharmacology 49.4 (2005): 436.
55. Borie-Swinburne, C., et al. "Effect of dietary protein on post-prandial glucose in patients with type 1 diabetes." Journal of Human Nutrition and Dietetics 26.6 (2013): 606-611.
56. Takahashi, Yoshinori, et al. "Effect of one-week administration of dipeptidyl peptidase-IV inhibitory peptides from chum salmon milt on postprandial blood glucose level: a randomised, placebo-controlled, double-blind, crossover, pilot clinical trial." Food & Function 12.18 (2021): 8544-8551
57. Monami, Matteo, et al. "Fasting and post-prandial glucose and diabetic complication. A meta-analysis." Nutrition, metabolism and cardiovascular diseases 23.7 (2013): 591-598.
58. Fang, Jinhai, et al. "Anomaly detection of diabetes data based on hierarchical clustering and CNN." Procedia Computer Science 199 (2022): 71-78.
59. Wild, Diane, et al. "A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education." Patient education and counseling 68.1 (2007): 10-15.
60. Cramer, Joyce A. "A systematic review of adherence with medications for diabetes." Diabetes care 27.5 (2004): 1218-1224.

61. Turner, Lauren Victoria. "The Timing of Walking and Post-Meal Blood Sugar Levels in Adults with Type 1 Diabetes." (2023).
62. Stoica, Roxana Adriana, et al. "Metformin indications, dosage, adverse reactions, and contraindications." Metformin. London, UK: IntechOpen, 2019
63. Brady, Peter A., and Aleksandar Jovanovic. "The sulfonylurea controversy: much ado about nothing or cause for concern?." Journal of the American College of Cardiology 42.6 (2003): 1022-1025.
64. Silver, Bahendeka, et al. "EADSG guidelines: insulin therapy in diabetes." Diabetes therapy 9 (2018): 449-492.
65. Hirsch, Irl B., Ruth Farkas-Hirsch, and Jay S. Skyler. "Intensive insulin therapy for treatment of type I diabetes." Diabetes Care 13.12 (1990): 1265-1283.
66. Lee, Shin-Hae, Shi-Young Park, and Cheol Soo Choi. "Insulin resistance: from mechanisms to therapeutic strategies." Diabetes & metabolism journal 46.1 (2022): 15.
67. Messerli, Franz H., Bryan Williams, and Eberhard Ritz. "Essential hypertension." The Lancet 370.9587 (2007): 591-603.
68. Onitilo, Adedayo A., et al. "Diabetes and cancer II: role of diabetes medications and influence of shared risk factors." Cancer Causes & Control 23 (2012): 991-1008.
69. Paneni, Francesco, Sarah Costantino, and Francesco Cosentino. "Insulin resistance, diabetes, and cardiovascular risk." Current atherosclerosis reports 16 (2014): 1-8.Retnakaran, Ravi, et al. "Risk factors for renal dysfunction in type 2 diabetes: UK Prospective Diabetes Study 74." diabetes 55.6 (2006): 1832-1839
70. Nampoothiri, Ram V., et al. "Renal dysfunction in patients with nonalcoholic fatty liver disease is related to the presence of diabetes mellitus and severity of liver disease." Journal of clinical and experimental hepatology 9.1 (2019): 22-28
71. Joyner, Michael J., Nisha Charkoudian, and B. Gunnar Wallin. "Sympathetic nervous system and blood pressure in humans: individualized patterns of regulation and their implications." Hypertension 56.1 (2010): 10-16. Antonaccio, Michael J. "Angiotensin converting enzyme (ACE) inhibitors." Annual review of pharmacology and toxicology 22.1 (1982): 57-87.
72. Barreras, Amy, and Cheryle Gurk-Turner. "Angiotensin II receptor blockers." Baylor University Medical Center Proceedings. Vol. 16. No. 1. Taylor & Francis, 2003.
73. Elliott, William J., and C. Venkata S. Ram. "Calcium channel blockers." The Journal of Clinical Hypertension 13.9 (2011): 687.
74. Roush, George C., Ramdeep Kaur, and Michael E. Ernst. "Diuretics: a review and update." Journal of cardiovascular pharmacology and therapeutics 19.1 (2014): 5-13.
75. Wiysonge, Charles S., et al. "Beta-blockers for hypertension." Cochrane database of systematic reviews 1 (2017).
76. Leasher, Janet L., et al. "Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010." Diabetes care 39.9 (2016): 1643-1649.
77. Bansal, Piyush, Rajendra P. Gupta, and Megha Kotecha. "Frequency of diabetic retinopathy in patients with diabetes mellitus and its correlation with duration of diabetes mellitus." Medical Journal of Dr. DY Patil University 6.4 (2013): 366-369.
78. Sahajpal, Nikhil S., et al. "Pathological perturbations in diabetic retinopathy: hyperglycemia, AGEs, oxidative stress and inflammatory pathways." Current Protein and Peptide Science 20.1 (2019): 92-110.
79. Gibson, Diane M. "Diabetic retinopathy and age-related macular degeneration in the US." American journal of preventive medicine 43.1 (2012): 48-54.
80. Kozioł, Milena, et al. "Regional analysis of diabetic retinopathy and co-existing social and demographic factors in the overall population of Poland." Archives of Medical Science: AMS 18.2 (2022): 320.

81. Kroc Collaborative Study Group*. "Blood glucose control and the evolution of diabetic retinopathy and albuminuria: a preliminary multicenter trial." New England Journal of Medicine 311.6 (1984): 365-372.
82. Çetin, Ebru N., et al. "Assessment of awareness of diabetic retinopathy and utilization of eye care services among Turkish diabetic patients." Primary care diabetes 7.4 (2013): 297-302.
83. Klein, R., and B. E. K. Klein. "Blood pressure control and diabetic retinopathy." British Journal of Ophthalmology 86.4 (2002): 365-367.
84. Smiddy, William E., and Harry W. Flynn Jr. "Vitrectomy in the management of diabetic retinopathy." Survey of ophthalmology 43.6 (1999): 491-507.
85. Bryl, Anna, et al. "The effect of diet and lifestyle on the course of diabetic retinopathy—a review of the literature." Nutrients 14.6 (2022): 1252.
86. Smokovski, Ivica. Managing diabetes in low income countries. springer, 2021.
87. Schectman, Joel M., Mohan M. Nadkarni, and John D. Voss. "The association between diabetes metabolic control and drug adherence in an indigent population." Diabetes care 25.6 (2002): 1015-1021.
88. Barker, E. M. (2020). When market forces fail: The case for federal regulation of insulin prices. Campbell L. Rev., 42, 311.
89. Nass, Sharyl J., Guru Madhavan, and Norman R. Augustine, eds. "Making medicines affordable: a national imperative." (2018).
90. Yeates, Karen, et al. "A global perspective on cardiovascular disease in vulnerable populations." Canadian Journal of Cardiology 31.9 (2015): 1081-1093.
91. Vaughan, Elizabeth M., et al. "Mentored implementation to initiate a diabetes program in an underserved community: a pilot study." BMJ Open Diabetes Research and Care 9.1 (2021): e002320.
92. Artinian, Nancy T., et al. "Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association." Circulation 122.4 (2010): 406-441.
93. Mohan, Viswanathan, et al. "Management of type 2 diabetes in developing countries: balancing optimal glycaemic control and outcomes with affordability and accessibility to treatment." Diabetes Therapy 11 (2020): 15-35.
94. Chow, Clara K., et al. "Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study." The lancet Diabetes & endocrinology 6.10 (2018): 798-808.